Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
The Importance of Seeing a Sarcoma Specialist
Michaela Mueller, event manager at the Sarcoma Foundation of America, discusses the importance of seeing a doctor who specializes in sarcoma.
Long-Term Effects of Ewing Sarcoma Are Minor, Study Finds
Many survivors of Ewing sarcoma have few complications and long-term side effects later on, according to a recent study.
Avoiding Amputation in Patients With Sarcoma
John E. Mullinax, M.D., discusses a chemotherapy strategy that may be able to save the limbs of some patients with sarcoma.
Novel Compound Offers Hope in Soft Tissue Sarcoma
A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.
PD-1 Blockades Show Potential in Sarcoma
Virginia Powers, Ph.D.
Patients with certain types of sarcoma may benefit from PD-1 blockades, according to a recent study.
Expert Discusses Local Control in Ewing Sarcoma
Dimosthenis Andreou, M.D., discussed the Euro-EWING99 trial with CURE.
Immunotherapy Continues to Move Into the Sarcoma Treatment Landscape
Immunotherapy's role for treating sarcoma is being cemented as more agents and targets are identified.
Reaching a Turning Point in the Advancement of Sarcoma Care
Treatment and imaging advancements are drastically changing the landscape of sarcoma care.
FDA Approves Lartruvo for Soft Tissue Sarcoma
A Lartruvo (olaratumab) combination received an accelerated approval from the FDA to treat patients with soft tissue sarcoma.
Neoadjuvant Therapy Shows Unexpected Benefit for High-Risk Soft Tissue Sarcoma
A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
What is your status?
Out of Treatment